Missouri AG Warns Eli Lilly Over 340B Drug Discount Data Demands

Missouri Attorney General Andrew Bailey has warned Eli Lilly to stop requiring hospitals to submit claims data as a condition for receiving discounted medicines under the federal 340B drug pricing program. The 340B program requires drugmakers to offer outpatient drugs at reduced prices to safety-net hospitals and clinics that serve low-income and rural patients. Lilly's data demands, according to the AG, create an unlawful barrier to the discounts and could disrupt care for vulnerable populations. This clash highlights growing tensions between pharmaceutical companies and 340B providers, with states increasingly pushing back against manufacturer restrictions. The outcome could set a precedent for how drugmakers may audit and verify 340B eligibility nationwide. As legal and regulatory battles escalate, hospitals and patients await clarity on whether such data requirements will be struck down or become a new industry standard.